Vital Therapies Announces Recent and Upcoming Scientific Presentations and Participation in Upcoming Investor Conference
- A presentation titled “Elaborating ELAD Mechanism of Action and Linking Cell-Based Models to the Clinic” was made on
September 9, 2017at the 18th International Symposium on Albumin Dialysis 2017 in Rostock-Hohe Düne, Germany.
- A poster presentation titled “Both MELD Score and Number of Organ Failures Defined by the Latest Chronic Liver Failure-Organ Failure Scoring System Effectively Select Subjects with Severe Alcoholic Hepatitis with Good Outcomes when Treated with the ELAD® System” will be presented at the
American Association for the Study of Liver Diseases (AASLD) Single Topic Conferencetitled “Acute on Chronic Liver Failure: Is it Ready for Clinical Practice?” taking place September 15-16, 2017in Chicago, IL.
- A poster presentation titled “Impact of the Systemic Inflammatory Response Syndrome on 3-month Mortality Rates in Subjects with Severe Alcoholic Hepatitis Treated with the ELAD System” will also be presented at the
AASLD Single Topic Conference, September 15-16, 2017in Chicago, IL.
- An electronic poster presentation titled “Ethanol-Induced Oxidative Stress in Primary Human Hepatocytes is Suppressed by VTL C3A Cell-Secreted Factors” will be presented at the
European Association for the Study of the Liver(EASL)-AASLD joint meeting “Definition, therapeutic advances and clinical endpoints in alcoholic liver disease and alcoholic hepatitis” to be held September 30-October 1, 2017in London, United Kingdom.
Posters and associated presentations are made available at http://ir.vitaltherapies.com in the "
The Company will be presenting at the 2017
Vice President, Investor Relations and Business Development